Wegovy's Summary of Product Characteristics (SmPC) contains warnings and precautions related to thyroid C-cell tumours , based on animal studies showing an increased risk of medullary thyroid carcinoma (MTC) in rodents
Some patients start noticing results within 23 months, with clinical studies showing an average of 14.9% body weight loss after 68 weeks
Semaglutide is generally suitable for adults
Step 2: The Bridge Therapies As you lower the dose of Semaglutide or Tirzepatide, we often introduce non-GLP-1 therapies to support your metabolism
Semaglutide vs Tirzepatide: A Researchers Comparison of GLP-1 and Dual-Incretin Agonists For the wider context, see our overview of research peptides for weight loss
The semaglutide titration continues with 0.5 mg weekly for four weeks, followed by 1.0 mg weekly for four weeks, then 1.7 mg weekly for four weeks, before reaching the target maintenance dose of 2.4 mg weekly